• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

可生物降解的脂质纳米颗粒可诱导RNA干扰介导的蛋白质敲低作用持续延长,并在小鼠和非人灵长类动物中表现出快速的肝脏清除率。

Biodegradable lipid nanoparticles induce a prolonged RNA interference-mediated protein knockdown and show rapid hepatic clearance in mice and nonhuman primates.

作者信息

Suzuki Yuta, Hyodo Kenji, Suzuki Takuya, Tanaka Yohei, Kikuchi Hiroshi, Ishihara Hiroshi

机构信息

DDS Research Group, Formulation Research Laboratories, Pharmaceutical Science and Technology, Medicine Development Center, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki 300-2635, Japan.

DDS Research Group, Formulation Research Laboratories, Pharmaceutical Science and Technology, Medicine Development Center, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki 300-2635, Japan.

出版信息

Int J Pharm. 2017 Mar 15;519(1-2):34-43. doi: 10.1016/j.ijpharm.2017.01.016. Epub 2017 Jan 9.

DOI:10.1016/j.ijpharm.2017.01.016
PMID:28089936
Abstract

Lipid nanoparticles based on ionizable lipids have been clinically validated as a means of delivery for RNA interference (RNAi) therapeutics. The ideal properties of RNAi carriers are efficient delivery of oligonucleotides into target cells and rapid elimination after the function is performed. Here, we report that degradable lipid nanoparticles are effective carriers of small interfering RNA (siRNA) and have a high therapeutic index. The newly developed degradable lipid nanoparticles carrying siRNA showed potent gene-silencing activity in mouse hepatocytes (ED≈0.02mg/kg siRNA). The ester bond in the lipid tail was hydrolyzed in the liver, resulting in rapid metabolism of the lipid. Toxicity assays showed that the degradable lipid was well-tolerated at siRNA doses of up to 16mg/kg in rats (over 800-fold higher than ED). A single intravenous injection of siRNA targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) in cynomolgus monkeys resulted in more than 90% protein silencing, and a 50% decrease in plasma low-density lipoprotein (LDL) cholesterol, with a measurable reduction for 2 months. Moreover, quantification of lipids in liver biopsies revealed rapid hepatic clearance of the degradable lipid in nonhuman primates. These degradable lipid nanoparticles with a high therapeutic index hold promise for RNA-based treatments.

摘要

基于可电离脂质的脂质纳米颗粒已在临床上被验证为RNA干扰(RNAi)疗法的一种递送手段。RNAi载体的理想特性是将寡核苷酸高效递送至靶细胞,并在功能执行后迅速清除。在此,我们报告可降解脂质纳米颗粒是小干扰RNA(siRNA)的有效载体,且具有高治疗指数。新开发的携带siRNA的可降解脂质纳米颗粒在小鼠肝细胞中显示出强大的基因沉默活性(ED≈0.02mg/kg siRNA)。脂质尾部的酯键在肝脏中水解,导致脂质快速代谢。毒性试验表明,在大鼠中,高达16mg/kg的siRNA剂量下,可降解脂质的耐受性良好(比ED高800多倍)。在食蟹猴中单次静脉注射靶向前蛋白转化酶枯草杆菌蛋白酶/kexin 9型(PCSK9)的siRNA导致超过90%的蛋白沉默,血浆低密度脂蛋白(LDL)胆固醇降低50%,且在2个月内可测量到降低。此外,肝活检中脂质的定量显示,在非人灵长类动物中可降解脂质在肝脏中迅速清除。这些具有高治疗指数的可降解脂质纳米颗粒有望用于基于RNA的治疗。

相似文献

1
Biodegradable lipid nanoparticles induce a prolonged RNA interference-mediated protein knockdown and show rapid hepatic clearance in mice and nonhuman primates.可生物降解的脂质纳米颗粒可诱导RNA干扰介导的蛋白质敲低作用持续延长,并在小鼠和非人灵长类动物中表现出快速的肝脏清除率。
Int J Pharm. 2017 Mar 15;519(1-2):34-43. doi: 10.1016/j.ijpharm.2017.01.016. Epub 2017 Jan 9.
2
Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo.最大限度地提高 siRNA 脂质纳米粒在体内肝脏基因沉默中的效力。
Angew Chem Int Ed Engl. 2012 Aug 20;51(34):8529-33. doi: 10.1002/anie.201203263. Epub 2012 Jul 10.
3
Enhanced Delivery of siRNA to Retinal Ganglion Cells by Intravitreal Lipid Nanoparticles of Positive Charge.带正电荷的玻璃体腔脂质纳米粒增强 siRNA 向视网膜神经节细胞的传递。
Mol Pharm. 2021 Jan 4;18(1):377-385. doi: 10.1021/acs.molpharmaceut.0c00992. Epub 2020 Dec 9.
4
siRNA-lipid nanoparticles with long-term storage stability facilitate potent gene-silencing in vivo.具有长期储存稳定性的 siRNA-脂质纳米颗粒在体内实现有效的基因沉默。
J Control Release. 2015 Dec 28;220(Pt A):44-50. doi: 10.1016/j.jconrel.2015.10.024. Epub 2015 Oct 19.
5
Engineering of small interfering RNA-loaded lipidoid-poly(DL-lactic-co-glycolic acid) hybrid nanoparticles for highly efficient and safe gene silencing: A quality by design-based approach.载小分子干扰 RNA 的脂质体-聚(DL-乳酸-共-乙醇酸)杂化纳米粒的工程化:基于质量源于设计的方法用于高效和安全的基因沉默。
Eur J Pharm Biopharm. 2017 Nov;120:22-33. doi: 10.1016/j.ejpb.2017.07.014. Epub 2017 Jul 26.
6
Quantitation of physiological and biochemical barriers to siRNA liver delivery via lipid nanoparticle platform.通过脂质纳米颗粒平台对小干扰RNA肝脏递送的生理和生化屏障进行定量分析。
Mol Pharm. 2014 May 5;11(5):1424-34. doi: 10.1021/mp400584h. Epub 2014 Apr 1.
7
Alterations in the hepatic transcriptional landscape after RNAi mediated ApoB silencing in cynomolgus monkeys.食蟹猴中RNAi介导的载脂蛋白B沉默后肝脏转录图谱的改变。
Atherosclerosis. 2015 Oct;242(2):383-95. doi: 10.1016/j.atherosclerosis.2015.07.032. Epub 2015 Jul 29.
8
Structure, activity and uptake mechanism of siRNA-lipid nanoparticles with an asymmetric ionizable lipid.具有不对称可离子化脂质的 siRNA-脂质纳米粒的结构、活性和摄取机制。
Int J Pharm. 2016 Aug 20;510(1):350-8. doi: 10.1016/j.ijpharm.2016.06.124. Epub 2016 Jun 29.
9
Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.针对枯草溶菌素转化酶 9 治疗血脂异常和动脉粥样硬化。
J Am Coll Cardiol. 2013 Oct 15;62(16):1401-8. doi: 10.1016/j.jacc.2013.07.056. Epub 2013 Aug 21.
10
Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.前蛋白转化酶枯草溶菌素 9 抑制:降低心血管疾病风险的新治疗机制。
Circulation. 2015 Oct 27;132(17):1648-66. doi: 10.1161/CIRCULATIONAHA.115.016080.

引用本文的文献

1
Species-specific gene expression manipulation in humanized livers of chimeric mice via siRNA-encapsulated lipid nanoparticle treatment.通过包裹小干扰RNA的脂质纳米颗粒处理在嵌合小鼠的人源化肝脏中进行物种特异性基因表达调控。
Mol Ther Methods Clin Dev. 2025 Apr 14;33(2):101466. doi: 10.1016/j.omtm.2025.101466. eCollection 2025 Jun 12.
2
Antibody-functionalized lipid nanocarriers for RNA-based cancer gene therapy: advances and challenges in targeted delivery.用于基于RNA的癌症基因治疗的抗体功能化脂质纳米载体:靶向递送的进展与挑战
Nanoscale Adv. 2025 Aug 22. doi: 10.1039/d5na00323g.
3
The role of excipients in lipid nanoparticle metabolism: implications for enhanced therapeutic effect.
辅料在脂质纳米颗粒代谢中的作用:对增强治疗效果的影响。
Ther Deliv. 2025 Jul;16(7):687-700. doi: 10.1080/20415990.2025.2506977. Epub 2025 May 29.
4
Functions and applications of RNA interference and small regulatory RNAs.RNA干扰和小调节RNA的功能及应用。
Acta Biochim Biophys Sin (Shanghai). 2024 Nov 18;57(1):119-130. doi: 10.3724/abbs.2024196.
5
Lipid-based Non-viral Vector: Promising Approach for Gene Delivery.基于脂质的非病毒载体:基因递送的有前景方法。
Curr Pharm Des. 2025;31(7):521-539. doi: 10.2174/0113816128324084240828084904.
6
Enhancing RNA-lipid nanoparticle delivery: Organ- and cell-specificity and barcoding strategies.增强 RNA-脂质纳米颗粒的递送:组织和细胞特异性及条码策略。
J Control Release. 2024 Nov;375:366-388. doi: 10.1016/j.jconrel.2024.08.030. Epub 2024 Sep 18.
7
Frameworks for transformational breakthroughs in RNA-based medicines.基于 RNA 的药物变革性突破的框架。
Nat Rev Drug Discov. 2024 Jun;23(6):421-444. doi: 10.1038/s41573-024-00943-2. Epub 2024 May 13.
8
Lymph node macrophages drive innate immune responses to enhance the anti-tumor efficacy of mRNA vaccines.淋巴结巨噬细胞驱动先天免疫反应以增强mRNA疫苗的抗肿瘤功效。
Mol Ther. 2024 Mar 6;32(3):704-721. doi: 10.1016/j.ymthe.2024.01.020. Epub 2024 Jan 18.
9
A holistic analysis of the intrinsic and delivery-mediated toxicity of siRNA therapeutics.siRNA 治疗药物的内在毒性和传递介导毒性的整体分析。
Adv Drug Deliv Rev. 2023 Oct;201:115052. doi: 10.1016/j.addr.2023.115052. Epub 2023 Aug 9.
10
Lipid nanoparticle-targeted mRNA formulation as a treatment for ornithine-transcarbamylase deficiency model mice.脂质纳米颗粒靶向的mRNA制剂作为鸟氨酸转氨甲酰酶缺乏症模型小鼠的一种治疗方法。
Mol Ther Nucleic Acids. 2023 Jul 4;33:210-226. doi: 10.1016/j.omtn.2023.06.023. eCollection 2023 Sep 12.